Biotech IPO performance outpaces AI sector in 2026 market cycle

Biotechnology initial public offerings have achieved a 55% average return, significantly outperforming recent artificial intelligence listings. This shift suggests a rotation in investor appetite toward clinical-stage healthcare assets despite the ongoing dominance of AI-related capital flows.